Word

BIOPALETTE

Status

Registered

Status Code

700

Status Date

Wednesday, October 9, 2019

Serial Number

79242171

Registration Number

5778150

Registration Date

Tuesday, June 18, 2019

Mark Type

4000

Filing Date

Tuesday, January 9, 2018

Published for Opposition

Tuesday, April 2, 2019

Trademark Owner History

Bio Palette Co., Ltd. - Original Registrant

Classifications

5 Living cells, microorganisms, proteins, peptides, nucleic acid sequences, and combinations thereof for medical diagnosis or veterinary diagnosis purposes; pharmaceutical preparations produced by genome or gene editing operation for treatment of genetic diseases; pharmaceutical preparations produced by genome or gene editing operation for modifying human microbiome; chemical reagents for medical purposes produced by genome or gene editing operation; chemical reagents for medical purposes in the field of genome or gene editing operation; cultures of microorganisms for medical or veterinary use produced by genome or gene editing operation; living cells, microorganisms, proteins, peptides, nucleic acid sequences, and combinations thereof for medical or veterinary purposes produced by genome or gene editing operation; biological cells for surgical implantation produced by genome or gene editing operation; pharmaceutical and biological preparations, and diagnostic products based on gene, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy for use in treatment of genetic diseases; pharmaceutical and biological preparations, and diagnostic products based on gene, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy for use in treatment of cancer; pharmaceutical and biological preparations, and diagnostic products based on gene, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy for use in modifying human microbiome; cultures of microorganisms for medical or veterinary purposes; biological tissue cultures for medical or veterinary purposes * all of the foregoing [ other than those ] produced by genome or gene editing operation *

1 Chemicals for use in industry and science; chemical reagents for use in genetic research other than for medical or veterinary purposes; chemical reagents for use in genetic research in the field of genome or gene editing other than for medical or veterinary purposes; chemical substances produced by genome or gene editing operation for analyses in laboratories, other than for medical or veterinary purposes; chemical reagent for separation and production of gene editing substances for non-medical purposes; biotechnologically-formed genes for use in the manufacture of agricultural seeds produced by genome or gene editing operation; cultures of microorganisms produced by genome or gene editing operation, other than for medical or veterinary use; diagnostic reagents for scientific or research use in the field of genome or gene editing; biotechnologically-formed genes for use in the manufacture of agricultural seeds; cultures of microorganisms, other than for medical or veterinary use

31 Crop seeds; plant seeds; crop seeds produced by genome or gene editing operation; plant seeds produced by genome or gene editing operation; crop seeds in which herbicide tolerance genes are incorporated by genome or gene editing operation; plant seeds in which herbicide tolerance genes are incorporated by genome or gene editing operation; vegetable seeds for planting produced by genome or gene editing operation; seeds for agricultural purposes; vegetable seeds for planting; seeds for planting; genetically modified seeds including seeds for agricultural purposes, flower seeds, seeds for planting, or vegetable seeds for planting

42 Research and development in the field of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems; scientific research in the field of genetics and genetic engineering; DNA screening for scientific research purposes; scientific and technological services, namely, research and development, quality control, and technical advisory services relating thereto in the fields of protein, antibody, and microorganism study, and the study of cells; structural and functional analysis of the genome with genome editing technology; DNA screening for scientific research purposes with genome editing technology; scientific and technological services, namely, research, development, technical advisory services, and information technology services, all relating to genome editing technology; scientific and technological services, namely, research and development, quality control, and technical advisory services relating thereto in the fields of protein, antibody, and microorganism study, and the study of cells, all with genome editing technology; scientific research and development in the field of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems with genome editing technology; scientific research in the field of genetics and genetic engineering with genome editing technology; testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs, all with genome editing technology; development of pharmaceuticals, cosmetics or foodstuffs, all with genome editing technology; technical advisory services relating to development of pharmaceuticals, cosmetics or foodstuffs, all with genome editing technology; information technology services relating to the development of pharmaceuticals, cosmetics or foodstuffs, all with genome editing technology; testing, inspection or research relating to medical treatment or medical technology with genome editing technology; information technology services for testing, inspection or research relating to medical treatment or medical technology with genome editing technology; testing or research relating to genome or gene to which genome editing technology is applied; scientific and medical research and survey in relation to bioinformatic tools in the fields of editing, modulation, modification, engineering, regulation, repair and therapy of gene, genome and cells to develop human pharmaceutical, biological preparations, and diagnostic products and services; scientific and technical research and development of bioinformatic tools in the fields of editing, modulation, modification, engineering, regulation, repair and therapy of gene, genome and cells to develop human pharmaceutical, biological preparations, and diagnostic products and services; research and development for the pharmaceutical industry and biotechnology industry with genome editing technology; research and development of biotechnology for others; research and development of genome editing technology for others; development of pharmaceutical preparations and medicines; biotechnology research; research and development in the field of genomics and biotechnology; technical advisory services in the field of genomics and biotechnology; structural and functional analysis of genomes; scientific and medical research in the fields of gene, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy to develop human pharmaceutical and biological preparations to be delivered or applied ex vivo to human cells for use in human therapeutics and diagnostic products and services; scientific study and research in the fields of gene, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy to develop human pharmaceutical and biological preparations to be delivered or applied ex vivo to human cells for use in human therapeutics and diagnostic products and services; design of bioinformatic algorithms and models for use in scientific and medical research in the fields of gene, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy to develop human pharmaceutical and biological preparations to be delivered or applied ex vivo to human cells for use in human therapeutics and diagnostic products and services; laboratory research in the field of pharmaceuticals; conducting clinical trials for others in the field of pharmaceuticals; laboratory research in the field of gene expression; research and development services in the field of gene expression systems; research and development services in the field of microorganisms and cells; scientific research services in the field of genetic engineering relating to plants

In the Statement, " international Class 5 " is amended per the TTAB order dated 9/24/2020
In the Statement, the following class 5 is updated per the Board Order dated July 23, 2020.

Trademark Events

Mar 18, 2023

Change Of Name/Address Rec'd From Ib

Jul 30, 2022

New Representative At Ib Received

Jun 9, 2021

Invalidation Reviewed - No Action Required By Office

Jun 6, 2021

Partial Invalidation Of Reg Ext Protection Created

Sep 30, 2020

Cancellation Terminated No. 999999

Sep 24, 2020

Amendment Under Section 7 ¿ Processed

Sep 24, 2020

Case Assigned To Post Registration Paralegal

Sep 24, 2020

Cancellation Denied No. 999999

Jul 23, 2020

Amendment Under Section 7 ¿ Processed

May 18, 2020

Registered - Sec. 7 Request Abandoned

May 18, 2020

Post Registration Action Mailed - Sec. 7

May 5, 2020

Case Assigned To Post Registration Paralegal

Apr 8, 2020

Teas Section 7 Request Received

Oct 18, 2019

Final Decision Transaction Processed By Ib

Oct 9, 2019

Cancellation Instituted No. 999999

Sep 28, 2019

Final Disposition Notice Sent To Ib

Sep 28, 2019

Final Disposition Processed

Sep 18, 2019

Final Disposition Notice Created, To Be Sent To Ib

Jun 18, 2019

Registered-Principal Register

Apr 2, 2019

Published For Opposition

Mar 13, 2019

Notice Of Publication

Feb 28, 2019

Approved For Pub - Principal Register

Feb 27, 2019

Teas/Email Correspondence Entered

Feb 27, 2019

Correspondence Received In Law Office

Feb 27, 2019

Assigned To Lie

Feb 22, 2019

Teas Response To Office Action Received

Nov 24, 2018

Refusal Processed By Ib

Nov 7, 2018

Non-Final Action Mailed - Refusal Sent To Ib

Nov 7, 2018

Refusal Processed By Mpu

Oct 24, 2018

Non-Final Action (Ib Refusal) Prepared For Review

Oct 23, 2018

Non-Final Action Written

Oct 16, 2018

Application Filing Receipt Mailed

Oct 10, 2018

Assigned To Examiner

Oct 10, 2018

New Application Office Supplied Data Entered

Oct 4, 2018

Sn Assigned For Sect 66a Appl From Ib